Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva Pharmaceutical Industries, a developer of generic drugs, has announced that its subsidiary, Teva Pharmaceuticals USA, has signed an agreement with AstraZeneca to settle patent litigation involving the company's US generic version of AstraZeneca's Pulmicort Respules including all claims for patent infringement and damages.
Subscribe to our email newsletter
Teva has previously launched its generic budesonide respules in the US. The agreement releases Teva for all past US sales of its generic budesonide respules and provides that any product already shipped by Teva will remain in the market to be further distributed and dispensed.
Teva will not resume shipping additional units of its budesonide respules until December 15, 2009 (or earlier based on certain contingencies) pursuant to an exclusive license for which Teva will pay AstraZeneca an undisclosed royalty.